Logo image of MLTX

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Overview

NASDAQ:MLTX - KY61559X1045 - Common Stock

60.155 USD
+0.44 (+0.73%)
Last: 9/5/2025, 1:32:49 PM

MLTX Key Statistics, Chart & Performance

Key Statistics
52 Week High61.87
52 Week Low31.42
Market Cap3.86B
Shares64.23M
Float53.77M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.78
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/bmo
IPO10-20 2020-10-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MLTX short term performance overview.The bars show the price performance of MLTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

MLTX long term performance overview.The bars show the price performance of MLTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 200 400 600

The current stock price of MLTX is 60.155 USD. In the past month the price increased by 13.19%. In the past year, price increased by 29.77%.

MOONLAKE IMMUNOTHERAPEUTICS / MLTX Daily stock chart

MLTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.99 373.89B
AMGN AMGEN INC 12.93 151.79B
GILD GILEAD SCIENCES INC 14.86 142.72B
VRTX VERTEX PHARMACEUTICALS INC 23.26 101.02B
REGN REGENERON PHARMACEUTICALS 12.44 60.18B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.51B
ARGX ARGENX SE - ADR 80.97 45.94B
ONC BEONE MEDICINES LTD-ADR 6.82 40.22B
INSM INSMED INC N/A 30.40B
BNTX BIONTECH SE-ADR N/A 26.84B
NTRA NATERA INC N/A 23.08B
BIIB BIOGEN INC 8.86 20.80B

About MLTX

Company Profile

MLTX logo image Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Company Info

MOONLAKE IMMUNOTHERAPEUTICS

Dorfstrasse 29

Zug ZUG CH

Employees: 100

MLTX Company Website

MLTX Investor Relations

Phone: 41415108022

MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ

What is the stock price of MOONLAKE IMMUNOTHERAPEUTICS today?

The current stock price of MLTX is 60.155 USD. The price increased by 0.73% in the last trading session.


What is the ticker symbol for MOONLAKE IMMUNOTHERAPEUTICS stock?

The exchange symbol of MOONLAKE IMMUNOTHERAPEUTICS is MLTX and it is listed on the Nasdaq exchange.


On which exchange is MLTX stock listed?

MLTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MOONLAKE IMMUNOTHERAPEUTICS stock?

22 analysts have analysed MLTX and the average price target is 80.26 USD. This implies a price increase of 33.42% is expected in the next year compared to the current price of 60.155. Check the MOONLAKE IMMUNOTHERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MOONLAKE IMMUNOTHERAPEUTICS worth?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a market capitalization of 3.86B USD. This makes MLTX a Mid Cap stock.


How many employees does MOONLAKE IMMUNOTHERAPEUTICS have?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) currently has 100 employees.


What are the support and resistance levels for MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a support level at 56.29. Check the full technical report for a detailed analysis of MLTX support and resistance levels.


Should I buy MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock pay dividends?

MLTX does not pay a dividend.


When does MOONLAKE IMMUNOTHERAPEUTICS (MLTX) report earnings?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of MOONLAKE IMMUNOTHERAPEUTICS (MLTX)?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.78).


What is the Short Interest ratio of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?

The outstanding short interest for MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is 9.98% of its float. Check the ownership tab for more information on the MLTX short interest.


MLTX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to MLTX. When comparing the yearly performance of all stocks, MLTX is one of the better performing stocks in the market, outperforming 84.4% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MLTX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MLTX. MLTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MLTX Financial Highlights

Over the last trailing twelve months MLTX reported a non-GAAP Earnings per Share(EPS) of -2.78. The EPS decreased by -205.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -38.29%
ROE -49.8%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-123.08%
Sales Q2Q%N/A
EPS 1Y (TTM)-205.49%
Revenue 1Y (TTM)N/A

MLTX Forecast & Estimates

22 analysts have analysed MLTX and the average price target is 80.26 USD. This implies a price increase of 33.42% is expected in the next year compared to the current price of 60.155.


Analysts
Analysts89.09
Price Target80.26 (33.42%)
EPS Next Y-77.8%
Revenue Next YearN/A

MLTX Ownership

Ownership
Inst Owners96.63%
Ins Owners10.94%
Short Float %9.98%
Short Ratio11.53